Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | KMO | O15229 | 1/20 | 0.32 |
| ▸ | IDE | P14735 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.31 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | VCP | P55072 | 2/20 | 0.30 |
| ▸ | RAF1 | P04049 | 2/20 | 0.30 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16785565 | 0.90 | RAF1 (0.35) | CA9KMOADORA2ACCNA2CDK2 | |
| SCHEMBL16775858 | 0.90 | RPS6KA2 (0.36) | RPS6KA2CA9EGFRKMOADORA2A | |
| SCHEMBL16775861 | 0.85 | VCP (0.36) | RPS6KA2CA9EGFRKMOADORA2A | |
| SCHEMBL16785650 | 0.81 | RAF1 (0.37) | CA9KMOADORA2ACCNA2CDK2 | |
| SCHEMBL16775985 | 0.79 | GRM5 (0.38) | KMT2AADORA2AMAPK1 | |
| SCHEMBL16776474 | 0.79 | FAAH (0.39) | RPS6KA2CA9KMOADORA2AVCP | |
| SCHEMBL16775872 | 0.78 | PIK3CA (0.33) | PIK3CAEGFRKMO | |
| SCHEMBL19670575 | 0.78 | EGFR (0.32) | PIK3CAEGFRKMOADORA2ACCNA2 | |
| SCHEMBL16775987 | 0.77 | KARS1 (0.36) | — | |
| SCHEMBL16776124 | 0.76 | CNR2 (0.38) | RPS6KA2EGFRKMOKMT2AVCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | RPS6KA2 2318/4885CA9 4248/4885PIK3CA 3691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.